Shares of Revance Therapeutics Inc. (NASDAQ:RVNC) dropped 1.5% during mid-day trading on Thursday . The company traded as low as $13.10 and last traded at $13.46, with a volume of 114,184 shares traded. The stock had previously closed at $13.66.

RVNC has been the topic of a number of research analyst reports. Zacks Investment Research lowered Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 13th. SunTrust Banks Inc. began coverage on Revance Therapeutics in a research report on Wednesday, March 23rd. They set a “buy” rating and a $46.00 price objective on the stock. Brean Capital reiterated a “buy” rating and set a $48.00 price objective on shares of Revance Therapeutics in a research report on Tuesday, May 24th. Finally, Guggenheim reiterated a “buy” rating and set a $55.00 price objective on shares of Revance Therapeutics in a research report on Monday, April 11th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Revance Therapeutics has a consensus rating of “Buy” and a consensus target price of $39.60.

The company’s 50 day moving average price is $15.62 and its 200-day moving average price is $19.08. The firm’s market cap is $393.97 million.

Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.12. During the same period in the previous year, the company earned ($0.65) EPS. Analysts expect that Revance Therapeutics Inc. will post ($3.53) EPS for the current fiscal year.

Other institutional investors have modified their holdings of the company. California State Teachers Retirement System increased its position in shares of Revance Therapeutics by 19.3% in the fourth quarter. California State Teachers Retirement System now owns 33,966 shares of the biopharmaceutical company’s stock worth $1,160,000 after buying an additional 5,492 shares during the period. Russell Frank Co purchased a new stake in Revance Therapeutics during the fourth quarter worth $1,384,000. Oxford Asset Management purchased a new stake in Revance Therapeutics during the fourth quarter worth $1,993,000. Columbus Circle Investors boosted its stake in Revance Therapeutics by 139.8% in the fourth quarter. Columbus Circle Investors now owns 61,295 shares of the biopharmaceutical company’s stock worth $2,094,000 after buying an additional 35,734 shares in the last quarter. Finally, Jennison Associates boosted its stake in Revance Therapeutics by 0.8% in the third quarter. Jennison Associates now owns 78,156 shares of the biopharmaceutical company’s stock worth $2,326,000 after buying an additional 603 shares in the last quarter.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.